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We read with interest the article by Erdem et al. reporting
absence of cerebrospinal fluid (CSF) pleocytosis (25 cells/ml) in 3%
(19/507) of HIV-negative tuberculous meningitis (TBM) patients
(Erdem et al., 2017).
We wish to highlight both the significance and higher incidence
of acellular CSF among HIV-infected adults with TBM. In reviewing
85 microbiologically-confirmed, HIV-associated TBM cases in
Uganda, 33% (28/85) had acellular CSF. Acellular CSF was also
commonly reported among other HIV-infected microbiologically-
confirmed TBM cohorts: 26% (5/19) in Zimbabwe, 19% (20/108) in
Brazil, and 21% (18/91) in Argentina (Table 1) (Cecchini et al., 2007;
Croda et al., 2010; Hakim et al., 2000; Vidal et al., 2010). Prevalence
of acellular CSF correlated with the severity of immunosuppres-
sion in the Argentinian cohort and occurred twice as often in CD4
counts <50 cells/ml (33%, 9/28) than with >50 cells/ml (15%, 5/31)
(Cecchini et al., 2009). In Vietnam, acellular CSF is less common
(4%, 20/461) despite advanced immunosuppression (median CD4
39 cells/ml). Variation between cohorts may be attributable to
variable time to CSF analysis, M. tuberculosis strain type, or genetic
differences in host immune responses between geographically
distinct cohorts.
In cryptococcal meningitis, both acellular CSF and elevated CSF
neutrophil counts have been associated with poorer outcomesTable 1
Summary HIV-infected cohorts with microbiologically confirmed tuberculous meningit
Cohort Uganda Zimbabwe 
(Hakim et al., 200
Study period 2011–2017 1994 
N 85 21 
Median CD4 cells/mL 81 131 
CSF lymphocytes/mm3 75 (0–2450) N/A 
Acellular CSF with 5 cells/mL 28 (33%) 5 (26%)b
Normal CSF (white cells, protein and glucose)a 3 (4%) 0 (0%) 
In hospital mortality 54%e 67% 
9-month mortality N/A N/A 
Mortality in patients with acellular CSF 39% N/A 
Mortality in patients with normal CSF 0% N/A 
Values represent N (%) or median (range).
N/A is not data available.
* Microbiologically confirmed HIV-associated TBM cases from Thao et al. Vietnam co
a “Normal CSF” defined as white cells 5/mm3, protein <45 g/l, glucose >45 mg/dl (
b CSF data available for n = 19.
c CSF data available for n = 91.
d CSF data available for 458.
e Outcome known for n = 69.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).(Scriven et al., 2015). Recently, the observation of a paucity of
inflammation or inappropriate neutrophil-mediated inflammation
adversely impacting survival has also been confirmed in TBM. Thao
et al. demonstrated that in Vietnamese adults lower CSF
lymphocyte count was an independent predictor of mortality,
regardless of HIV-status (Thao et al., 2017) and van Laarhoven et al.
found that high CSF neutrophils were associated with death in a
large Indonesian, predominantly HIV-negative, cohort (van Laar-
hoven et al., 2017).
In HIV-infection, the degree of immunosuppression affects the
intracerebral inflammatory phenotype. Those with CD4+ T-cell
count <150 cells/ml had a higher median CSF neutrophil
percentage than those with CD4+ count >150 cells/ml (25% versus
10%, P = 0.021) and this correlated with higher CSF cytokine
concentrations (Thuong et al., 2017). Both increased CSF neutro-
phils and raised inflammatory mediator concentrations predispose
to clinical deterioration after starting HIV therapy, resulting in
higher morbidity and mortality (Marais et al., 2014). This
inflammation may contribute to the 44% mortality reported by
Thuong in those with <150 CD4 cells/ml compared with 13%
mortality in >150 CD4 cells/ml. Improved understanding of the
drivers and consequences of the inflammatory phenotype in
HIV-associated TBM may enable optimised use of adjunctive
corticosteroids or host-directed therapy.
“Typical” CSF findings (cells >5/ml, protein >45 g/l, glucose
<45 mg/dl) occur in under two-thirds of HIV-infected TBM
patients, so clinical acumen and highly sensitive diagnostic tests
are critical (Croda et al., 2010). The new Xpert MTB/Rif ‘Ultra’ assay
has greater analytical sensitivity and may reduce diagnosticis.
Brazil Argentina Vietnam
0) (Croda et al., 2010) (Cecchini et al., 2007, 2009) (Thao et al., 2017)*
1999–2007 1996–2004 2004–2015
108 101 461
65 53 39
49 (0–100) N/A 103 (0–6004)
20 (19%) 18 (21%)c 20 (4%)d
4 (4%) N/A 2 (0.4%)
29% 63% N/A
41% N/A 51%
55% N/A 60%
75% N/A 100%
hort included.
2.5 mmol/l).
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78 Letter to the Editor / International Journal of Infectious Diseases 68 (2018) 77–78dilemma in HIV-associated TBM (Bahr et al., 2018). These data
should reinforce that acellular CSF is a poor prognostic sign and is
relatively common among HIV-infected persons, 12% (91/776)
among the cohorts summarized. High clinical index of suspicion
remains vital for timely, often empiric TBM therapy to reduce
death and disability.
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